Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Everolimus in Pediatric Brain Tumors
NCT03387020Phase 1Completed
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Jan 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in malignant glioma, medulloblastoma, central nervous system embryonal tumor and 3 more, sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Maximum Tolerated Dose of Ribociclib and Everolimus at 4 weeks and Average Tumor and Plasma Concentrations of Ribociclib. Started Jan 2018; status: completed.
02
Drugs
ribociclib
03
Conditions
malignant gliomamedulloblastomacentral nervous system embryonal tumorependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT03387020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387020.